A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate. * Radiologic evidence of metastatic disease (Jewett-Whitmore Stages D1-D2 or TNM Stage N1-3 or M1). * Disease progression or recurrence documented by either: increasing serum PSA on three consecutive measurements each obtained at least one week apart, or findings on radiographic imaging studies. * Non-surgically castrate subjects must be receiving androgen ablation therapy as maintenance therapy. * Adequate hormonal therapy as documented by a castrate level of serum testosterone (all subjects without surgical castration must have a serum testosterone less than 50 ng/ml). * At least 4 weeks must have elapsed after the withdrawal of antiandrogens (6 weeks in the case of bicalutamide). * Age 18 years and over. Subjects older than 80 years should be entered on study only if considered "physiologically appropriate" for combination chemotherapy. * ECOG performance score (PS) of 0 or 1. * Stable levels of pain for at least 7 days before study entry. * Life expectancy more than 3 months. * At least 28 days must have elapsed since prior radiotherapy. * At least 28 days must have elapsed since any prior investigational agent. * Absolute neutrophil count (ANC) at least 1.5 x 10\^9th/L. * Platelet count at least 100 x 10\^9th/L. * Hemoglobin at least 10 g/dL. * Serum AST and ALT levels ≥ 1.5 times upper limit of normal (ULN). * Serum bilirubin ≤ ULN. * Serum creatinine ≤ ULN. * All subjects m…